Gilead Reports Interim Results of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in BICSTaR Study to Treat HIV

Shots:

• The ongoing BICSTaR study evaluates the antiviral effectiveness & safety of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) in 1135 patients with HIV across the EU, Canada & Israel
• The study demonstrated clinical & PROs that showed a consistent efficacy profile in a real-world setting. In 2nd analysis, 97% & 96% of treatment-naïve & experienced adults achieved & maintained virologic suppression after 1yrs. of treatment, 91% patients had high persistence with Biktarvy in both groups, was well-tolerated with no resistance
• The additional data also presented at EACS 2021 includes a P-III 1878 study that showed the durable efficacy of Biktarvy

Click here to­ read the full press release/ article | Ref: Gilead | Image: Reuters